Zoom's 'hidden gem' investment in Anthropic could be worth $2 billion to $4 billion, analysts say — Positive
ZM CNBC — January 26, 2026Shares of Zoom popped on Monday after analysts at Baird estimated that the company's investment in the AI startup Anthropic could be worth billions. Anthropic announced a partnership with Zoom and revealed that Zoom Ventures had invested in the company in May 2023.
Why Karooooo (KARO) Might be Well Poised for a Surge — Positive
KARO Zacks Investment Research — January 26, 2026Karooooo Ltd. (KARO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Earnings Estimates Rising for Interactive Brokers (IBKR): Will It Gain? — Positive
IBKR Zacks Investment Research — January 26, 2026Interactive Brokers Group, Inc. (IBKR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
INVESTOR ALERT: Investigation of Beta Bionics, Inc. (BBNX) by Holzer & Holzer, LLC — Neutral
BBNX GlobeNewsWire — January 26, 2026ATLANTA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) complied with federal securities laws. On January 8, 2026, Beta Bionics announced preliminary, unaudited fourth quarter 2025 topline financial results, reporting that new patient starts, or the total number of individuals who have initiated use of the iLet Bionic Pancreas System, are expected to be below analyst estimates for the fourth quarter. Following this news, the price of the Company's stock dropped.
INVESTOR ALERT: Investigation of Mereo BioPharma Group plc (MREO) by Holzer & Holzer, LLC — Neutral
MREO GlobeNewsWire — January 26, 2026ATLANTA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO) complied with federal securities laws. On December 29, 2025, Mereo announced the results from its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, revealing that, “[n]either study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.” Following this news, the price of the Company's stock dropped.
USA Rare Earth Is Surging. A Big Government Funding Deal Is Lifting the Stock — Positive
USAR Investopedia — January 26, 2026USA Rare Earth (USAR) is starting the week on a high note with a public-private funding deal that is lifting the company's shares.
Why Owens Corning (OC) is Poised to Beat Earnings Estimates Again — Positive
OC Zacks Investment Research — January 26, 2026Owens Corning (OC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why eBay (EBAY) is Poised to Beat Earnings Estimates Again — Positive
EBAY Zacks Investment Research — January 26, 2026eBay (EBAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Skyward (SKWD) Beat Estimates Again in Its Next Earnings Report? — Positive
SKWD Zacks Investment Research — January 26, 2026Skyward (SKWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again — Positive
VCYT Zacks Investment Research — January 26, 2026Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Entergy (ETR) Beat Estimates Again in Its Next Earnings Report? — Positive
ETR Zacks Investment Research — January 26, 2026Entergy (ETR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will ADM (ADM) Beat Estimates Again in Its Next Earnings Report? — Positive
ADM Zacks Investment Research — January 26, 2026ADM (ADM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Arhaus, Inc. (ARHS) Beat Estimates Again in Its Next Earnings Report? — Positive
ARHS Zacks Investment Research — January 26, 2026Arhaus, Inc. (ARHS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Amer Sports, Inc. (AS) is Poised to Beat Earnings Estimates Again — Positive
AS Zacks Investment Research — January 26, 2026Amer Sports, Inc. (AS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will BWX (BWXT) Beat Estimates Again in Its Next Earnings Report? — Positive
BWXT Zacks Investment Research — January 26, 2026BWX (BWXT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Comstock (CRK) is Poised to Beat Earnings Estimates Again — Positive
CRK Zacks Investment Research — January 26, 2026Comstock (CRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Expeditors International (EXPD) Beat Estimates Again in Its Next Earnings Report? — Positive
EXPD Zacks Investment Research — January 26, 2026Expeditors International (EXPD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Clorox (CLX) Beat Estimates Again in Its Next Earnings Report? — Positive
CLX Zacks Investment Research — January 26, 2026Clorox (CLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Federal Signal (FSS) Beat Estimates Again in Its Next Earnings Report? — Positive
FSS Zacks Investment Research — January 26, 2026Federal Signal (FSS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Merit Medical (MMSI) is Poised to Beat Earnings Estimates Again — Positive
MMSI Zacks Investment Research — January 26, 2026Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
